Cargando…
Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors
PURPOSE: Radical resection is paramount for curative oncological surgery. Fluorescence-guided surgery (FGS) aids in intraoperative identification of tumor-positive resection margins. This study aims to assess the feasibility of urokinase plasminogen activator receptor (uPAR) targeting antibody fragm...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970952/ https://www.ncbi.nlm.nih.gov/pubmed/34642899 http://dx.doi.org/10.1007/s11307-021-01657-2 |
_version_ | 1784898006845227008 |
---|---|
author | Baart, Victor M. van Manen, Labrinus Bhairosingh, Shadhvi S. Vuijk, Floris A. Iamele, Luisa de Jonge, Hugo Scotti, Claudia Resnati, Massimo Cordfunke, Robert A. Kuppen, Peter J. K. Mazar, Andrew P. Burggraaf, Jacobus Vahrmeijer, Alexander L. Sier, Cornelis F. M. |
author_facet | Baart, Victor M. van Manen, Labrinus Bhairosingh, Shadhvi S. Vuijk, Floris A. Iamele, Luisa de Jonge, Hugo Scotti, Claudia Resnati, Massimo Cordfunke, Robert A. Kuppen, Peter J. K. Mazar, Andrew P. Burggraaf, Jacobus Vahrmeijer, Alexander L. Sier, Cornelis F. M. |
author_sort | Baart, Victor M. |
collection | PubMed |
description | PURPOSE: Radical resection is paramount for curative oncological surgery. Fluorescence-guided surgery (FGS) aids in intraoperative identification of tumor-positive resection margins. This study aims to assess the feasibility of urokinase plasminogen activator receptor (uPAR) targeting antibody fragments for FGS in a direct comparison with their parent IgG in various relevant in vivo models. PROCEDURES: Humanized anti-uPAR monoclonal antibody MNPR-101 (uIgG) was proteolytically digested into F(ab’)2 and Fab fragments named uFab2 and uFab. Surface plasmon resonance (SPR) and cell assays were used to determine in vitro binding before and after fluorescent labeling with IRDye800CW. Mice bearing subcutaneous HT-29 human colonic cancer cells were imaged serially for up to 120 h after fluorescent tracer administration. Imaging characteristics and ex vivo organ biodistribution were further compared in orthotopic pancreatic ductal adenocarcinoma (BxPc-3-luc2), head-and-neck squamous cell carcinoma (OSC-19-luc2-GFP), and peritoneal carcinomatosis (HT29-luc2) models using the clinical Artemis fluorescence imaging system. RESULTS: Unconjugated and conjugated uIgG, uFab2, and uFab specifically recognized uPAR in the nanomolar range as determined by SPR and cell assays. Subcutaneous tumors were clearly identifiable with tumor-to-background ratios (TBRs) > 2 after 72 h for uIgG-800F and 24 h for uFab2-800F and uFab-800F. For the latter two, mean fluorescence intensities (MFIs) dipped below predetermined threshold after 72 h and 36 h, respectively. Tumors were easily identified in the orthotopic models with uIgG-800F consistently having the highest MFIs and uFab2-800F and uFab-800F having similar values. In biodistribution studies, kidney and liver fluorescence approached tumor fluorescence after uIgG-800F administration and surpassed tumor fluorescence after uFab2-800F or uFab-800F administration, resulting in interference in the abdominal orthotopic mouse models. CONCLUSIONS: In a side-by-side comparison, FGS with uPAR-targeting antibody fragments compared with the parent IgG resulted in earlier tumor visualization at the expense of peak fluorescence intensity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01657-2. |
format | Online Article Text |
id | pubmed-9970952 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-99709522023-03-01 Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors Baart, Victor M. van Manen, Labrinus Bhairosingh, Shadhvi S. Vuijk, Floris A. Iamele, Luisa de Jonge, Hugo Scotti, Claudia Resnati, Massimo Cordfunke, Robert A. Kuppen, Peter J. K. Mazar, Andrew P. Burggraaf, Jacobus Vahrmeijer, Alexander L. Sier, Cornelis F. M. Mol Imaging Biol Research Article PURPOSE: Radical resection is paramount for curative oncological surgery. Fluorescence-guided surgery (FGS) aids in intraoperative identification of tumor-positive resection margins. This study aims to assess the feasibility of urokinase plasminogen activator receptor (uPAR) targeting antibody fragments for FGS in a direct comparison with their parent IgG in various relevant in vivo models. PROCEDURES: Humanized anti-uPAR monoclonal antibody MNPR-101 (uIgG) was proteolytically digested into F(ab’)2 and Fab fragments named uFab2 and uFab. Surface plasmon resonance (SPR) and cell assays were used to determine in vitro binding before and after fluorescent labeling with IRDye800CW. Mice bearing subcutaneous HT-29 human colonic cancer cells were imaged serially for up to 120 h after fluorescent tracer administration. Imaging characteristics and ex vivo organ biodistribution were further compared in orthotopic pancreatic ductal adenocarcinoma (BxPc-3-luc2), head-and-neck squamous cell carcinoma (OSC-19-luc2-GFP), and peritoneal carcinomatosis (HT29-luc2) models using the clinical Artemis fluorescence imaging system. RESULTS: Unconjugated and conjugated uIgG, uFab2, and uFab specifically recognized uPAR in the nanomolar range as determined by SPR and cell assays. Subcutaneous tumors were clearly identifiable with tumor-to-background ratios (TBRs) > 2 after 72 h for uIgG-800F and 24 h for uFab2-800F and uFab-800F. For the latter two, mean fluorescence intensities (MFIs) dipped below predetermined threshold after 72 h and 36 h, respectively. Tumors were easily identified in the orthotopic models with uIgG-800F consistently having the highest MFIs and uFab2-800F and uFab-800F having similar values. In biodistribution studies, kidney and liver fluorescence approached tumor fluorescence after uIgG-800F administration and surpassed tumor fluorescence after uFab2-800F or uFab-800F administration, resulting in interference in the abdominal orthotopic mouse models. CONCLUSIONS: In a side-by-side comparison, FGS with uPAR-targeting antibody fragments compared with the parent IgG resulted in earlier tumor visualization at the expense of peak fluorescence intensity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11307-021-01657-2. Springer International Publishing 2021-10-12 2023 /pmc/articles/PMC9970952/ /pubmed/34642899 http://dx.doi.org/10.1007/s11307-021-01657-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Baart, Victor M. van Manen, Labrinus Bhairosingh, Shadhvi S. Vuijk, Floris A. Iamele, Luisa de Jonge, Hugo Scotti, Claudia Resnati, Massimo Cordfunke, Robert A. Kuppen, Peter J. K. Mazar, Andrew P. Burggraaf, Jacobus Vahrmeijer, Alexander L. Sier, Cornelis F. M. Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors |
title | Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors |
title_full | Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors |
title_fullStr | Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors |
title_full_unstemmed | Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors |
title_short | Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors |
title_sort | side-by-side comparison of upar-targeting optical imaging antibodies and antibody fragments for fluorescence-guided surgery of solid tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970952/ https://www.ncbi.nlm.nih.gov/pubmed/34642899 http://dx.doi.org/10.1007/s11307-021-01657-2 |
work_keys_str_mv | AT baartvictorm sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT vanmanenlabrinus sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT bhairosinghshadhvis sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT vuijkflorisa sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT iameleluisa sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT dejongehugo sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT scotticlaudia sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT resnatimassimo sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT cordfunkeroberta sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT kuppenpeterjk sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT mazarandrewp sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT burggraafjacobus sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT vahrmeijeralexanderl sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors AT siercornelisfm sidebysidecomparisonofupartargetingopticalimagingantibodiesandantibodyfragmentsforfluorescenceguidedsurgeryofsolidtumors |